← Back to Discover
GILEAD SCIENCES, INC.
Period ended Sep 30, 2026 · Latest filing Nov 6, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Sep 30, 2026: $1,463,841,605
More quarters will appear as history becomes available.
Top holdings
Top 10 at Sep 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Arcus Biosciences Inc. · COM · 03969F109 · shares: $811,701,551
- Lakefront Biotherapeutics · SPON ADR · 36315X101 · shares: $501,284,604
- Assembly Biosciences Inc. · COM NEW · 045396207 · shares: $116,911,821
- Kyverna Therapeutics Inc. · COM · 501976104 · shares: $28,057,609
- Xilio Therapeutics Inc. · COM · 98422T100 · shares: $5,886,020
Reported holdings
5 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Arcus Biosciences Inc. | COM | 03969F109 | — | 31,424,760 shares | $811,701,551 |
| Lakefront Biotherapeutics | SPON ADR | 36315X101 | — | 16,707,477 shares | $501,284,604 |
| Assembly Biosciences Inc. | COM NEW | 045396207 | — | 4,977,089 shares | $116,911,821 |
| Kyverna Therapeutics Inc. | COM | 501976104 | — | 4,126,119 shares | $28,057,609 |
| Xilio Therapeutics Inc. | COM | 98422T100 | — | 650,389 shares | $5,886,020 |